Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
17
pubmed:dateCreated
2009-9-1
pubmed:abstractText
The conformational flexibility exhibited by protein kinases poses an enormous challenge to the design of cancer therapeutics. Additionally the high degree of structural conservation within the kinase superfamily often leads to inhibitors that exhibit little selectivity and substantial cross reactivity. This work investigates the conformational changes that accompany the binding of Gleevec, or imatinib mesylate, to the tyrosine kinases c-Kit and c-Abl. Our analysis is that this fit is driven, at least in part, by the need to exclude water from solvent-exposed backbone hydrogen bonds. Both experimental and molecular modeling studies of the active state inhibitor of the tyrosine kinase c-Abl indicate that solvent exclusion also plays a role in this system.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
http://linkedlifedata.com/resource/pubmed/chemical/9-hydroxyellipticine, http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, http://linkedlifedata.com/resource/pubmed/chemical/Ellipticines, http://linkedlifedata.com/resource/pubmed/chemical/FGFR2 protein, human, http://linkedlifedata.com/resource/pubmed/chemical/Ligands, http://linkedlifedata.com/resource/pubmed/chemical/Piperazines, http://linkedlifedata.com/resource/pubmed/chemical/Protein Kinase Inhibitors, http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins c-abl, http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins c-kit, http://linkedlifedata.com/resource/pubmed/chemical/Pyrimidines, http://linkedlifedata.com/resource/pubmed/chemical/Receptor, Fibroblast Growth..., http://linkedlifedata.com/resource/pubmed/chemical/Water, http://linkedlifedata.com/resource/pubmed/chemical/imatinib
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
1873-3468
pubmed:author
pubmed:issnType
Electronic
pubmed:day
3
pubmed:volume
583
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
2899-906
pubmed:dateRevised
2009-11-19
pubmed:meshHeading
pubmed-meshheading:19660459-Amino Acid Sequence, pubmed-meshheading:19660459-Antineoplastic Agents, pubmed-meshheading:19660459-Ellipticines, pubmed-meshheading:19660459-Enzyme Activation, pubmed-meshheading:19660459-Humans, pubmed-meshheading:19660459-Hydrogen Bonding, pubmed-meshheading:19660459-Ligands, pubmed-meshheading:19660459-Models, Molecular, pubmed-meshheading:19660459-Molecular Sequence Data, pubmed-meshheading:19660459-Molecular Structure, pubmed-meshheading:19660459-Mutation, pubmed-meshheading:19660459-Piperazines, pubmed-meshheading:19660459-Protein Kinase Inhibitors, pubmed-meshheading:19660459-Protein Structure, Tertiary, pubmed-meshheading:19660459-Proto-Oncogene Proteins c-abl, pubmed-meshheading:19660459-Proto-Oncogene Proteins c-kit, pubmed-meshheading:19660459-Pyrimidines, pubmed-meshheading:19660459-Receptor, Fibroblast Growth Factor, Type 2, pubmed-meshheading:19660459-Sequence Alignment, pubmed-meshheading:19660459-Water
pubmed:year
2009
pubmed:articleTitle
Tyrosine kinase inhibition: Ligand binding and conformational change in c-Kit and c-Abl.
pubmed:affiliation
Department of Chemistry, St. Edward's University, Austin, TX 78704, USA. healy@stedwards.edu
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't